Est. 2026 — Neurochemical Data Layer
Seroix builds the data and clinical infrastructure for companies working at the frontier of serotonergic medicine — from SSRI response analytics to psychedelic therapy platforms and gut-brain axis research.
Serotonin (Latin: serum + Greek: tonos = tension) — the molecule at the center of mood, cognition, and the psychedelic medicine revolution.// Core infrastructure
Longitudinal treatment response tracking for serotonergic medications — from baseline symptom scoring to remission rates and side effect profiling. Built for psychiatric digital health and clinical trial platforms.
Structured data infrastructure for psilocybin, MDMA, and ketamine-assisted therapy outcomes — session tracking, integration protocols, and long-term follow-up analytics for KAP and PAP platforms.
Integrate serotonin biomarkers, tryptophan metabolism panels, and microbiome-serotonin correlates into your clinical platform — the data layer for the emerging gut-brain therapeutics market.
// Why now
Serotonin is the most universally recognized neurochemical. The clinical infrastructure around it is still generic.
Every person who has ever discussed antidepressants, mental health, or psychedelics knows what serotonin is. It is the one neurochemical that requires zero explanation — to patients, investors, clinicians, or founders. That universal recognition is extraordinarily rare in medicine.
Yet the data infrastructure supporting serotonergic medicine remains fragmented. Psychiatric platforms track symptoms but not neurochemistry. Psychedelic therapy companies collect outcomes data in spreadsheets. Gut-brain research runs on academic tools not built for clinical deployment.
Seroix is the infrastructure layer that the serotonin economy needs — from SSRI optimization to psychedelic therapy to next-generation gut-brain therapeutics.
// Get in touch
We are selectively onboarding infrastructure partners and early customers. Tell us about your platform and what you are building in serotonergic or psychedelic medicine.